Submit Manuscript  

Article Details

Radioiodinated Agents for Imaging Multidrug Resistant Tumors

[ Vol. 5 , Issue. 2 ]


Zbigniew P. Kortylewicz, Ann M. Augustine, Jessica Nearman, Jonathon McGarry and Janina Baranowska-Kortylewicz   Pages 171 - 181 ( 11 )


Diagnostic agents enabling characterization of multidrug resistance (MDR) in tumors can aid in the selection of chemotherapy regimens. We report here synthesis and evaluation of radiopharmaceuticals based on the second-generation MDR-reversing drug MS-209. 5-[3-{4-(2-Phenyl-2-(4-[125I]iodo-phenyl)acetyl)piperazin-1-yl}-2-hydroxypropoxy]quinoline (17) was prepared from the 4-tributylstannyl precursor (16) in > 95% radiochemical yield. (16) was synthesized in a six-step process with the overall yield of 25%. In vitro studies were conducted in MES-SA (drug-sensitive) and MESSA/ Dx5 (MDR) human uterine sarcoma cell lines. In vivo studies were performed in athymic mice bearing MES-SA and MES-SA/Dx5 xenografts. The uptake of (17) is higher in MES-SA than MES-SA/Dx5 cells. The uptake and efflux of (17) depend on temperature and concentration, and indicate active transport mechanism(s). Incubation of drug sensitive MES-SA cells with verapamil or (15), a nonradioactive analog of (17), alters the cellular retention of radioactivity only marginally. However, MESSA/ Dx5 cells retain ∼12% more of (17) when incubated with 10 μM verapamil. The addition of (15) or high concentrations of (17) also increase the uptake of (17) in MES-SA/Dx5 up to 200%, depending on the concentration and temperature. The dependence of (17) uptake on the MDR status is also evident in the ex vivo binding studies. In vivo tests in mice xenografted simultaneously with both tumor cell lines indicate distinct pharmacokinetics for each tumor. The absorption half-life in MES-SA/Dx5 xenograft is ∼10x shorter and the mean residence time ∼50% shorter compared to MES-SA xenograft in the same mouse. Radioiodinated derivatives of MS-209 appear to be good indicators of multidrug resistance. For supplement material, please see the online version of the article.


Multidrug resistance, imaging, radioiodine, uterine sarcoma, quinoline derivatives


University of Nebraska Medical Center, Department of Radiation Oncology, J. Bruce Henriksen Laboratories for Cancer Research, 986850 Nebraska Health System, Omaha, Nebraska 68198-6850, USA.

Read Full-Text article